A preference trial with rizatriptan 10 mg and ibuprofen 400 mg in migraine patients in the general practice

Merck Sharp and Dohme BV (MSD) (The Netherlands)0 个研究点目标入组 35 人开始时间: 2005年5月16日最近更新: 2015年1月13日

适应症

试验速览

暂无简介。

•1. At least 18 years of age at visit 1
•2. Current history of migraine with or without aura according to the International Headache Society (IHS) criteria
•3. Experienced an average of at least one migraine attack per month for six months prior to entry to the study
•4. Naïve to the use of 5HT1 agonists and ergotamine
•5. Willing and able to understand and complete questionnaires
•6. Willing and able to give informed consent prior to entry into the study

•1. A history suggestive of ischaemic heart disease (IHD) (e.g. angina pectoris) or any atherosclerotic disease which places them at increased risk of coronary ischaemia
•2. A history of cerebrovascular accident (CVA) or transient ischaemic attack (TIA)
•3. A history of hypertension or a current blood pressure above 160/95 mmHg (measured three times)
•4. A history of basilar, hemiplegic or ophtalmoplegic migraine
•5. Impaired hepatic or renal function
•6. A history of gastrointestinal disease
•7. A history of asthma
•8. Have a known or suspected hypersensitivity to, intolerance of, or contraindications to any component of the study medication
•9. Currently use propanolol as a prophylactic agent
•10. Currently use monoamine oxidase (MAO) inhibitors
•11. Currently abuse alcohol, analgesics or psychotropic drugs
•12. A history of hypertension
•13. Any severe concurrent medical condition, which may affect the interpretation in a clinical trial
•14. Females who are pregnant or breastfeeding, and females of childbearing potential who are not using a medically acceptable form of contraception
•15. Have participated in a clinical trial within the previous month or are currently participating in any other clinical research study or clinical trial

发起方

Merck Sharp and Dohme BV (MSD) (The Netherlands)